DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Binosto (Alendronate Sodium) - Published Studies


Binosto Related Published Studies

Well-designed clinical trials related to Binosto (Alendronate)

A randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone. [2014]

Targeted anti-inflammatory systemic therapy for restenosis: The Biorest Liposomal Alendronate with Stenting sTudy (BLAST)-a double blind, randomized clinical trial. [2013]

Comparing tolerability and efficacy of generic versus brand alendronate: a randomized clinical study in postmenopausal women with a recent fracture. [2013]

Effects of adding alendronate to ongoing hormone therapy on bone mineral density in postmenopausal Korean women: a randomized, double-blind, placebo-controlled clinical trial. [2013]

Targeted anti-inflammatory systemic therapy for restenosis: the Biorest Liposomal Alendronate with Stenting sTudy (BLAST)-a double blind, randomized clinical trial. [2013]

Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials. [2012]

Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. [2010]

Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. [2010]

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. [2010]

Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial. [2009]

A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis. [2009]

Alendronate/vitamin D3 70 mg/2800 IU with and without additional 2800 IU vitamin D3 for osteoporosis: results from the 24-week extension of a 15-week randomized, controlled trial. [2009]

Randomized, active-controlled study of once-weekly alendronate 280 mg high dose oral buffered solution for treatment of Paget's disease. [2009]

Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss. [2008]

Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density. [2007]

Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis. [2007]

Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis. [2007]

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. [2006]

Effects of a combined alendronate and calcitriol agent (Maxmarvil) on bone metabolism in Korean postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study. [2006]

Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial. [2006]

Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. [2006]

Alendronate/colecalciferol. [2005]

Impact of alendronate on quality of life in children with osteogenesis imperfecta. [2005]

A randomized, placebo-controlled, 6-month study of once-weekly alendronate oral solution for postmenopausal osteoporosis. [2005]

Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study. [2005]

Effect of hormone replacement, alendronate, or combination therapy on hip structural geometry: a 3-year, double-blind, placebo-controlled clinical trial. [2005]

Monitoring alendronate and estradiol therapy with quantitative ultrasound and bone mineral density. [2005]

Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. [2005]

Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures. [2005]

Alendronate for the treatment of osteopenia in anorexia nervosa: a randomized, double-blind, placebo-controlled trial. [2005]

Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of-1.6 to -2.5 at the femoral neck: the Fracture Intervention Trial. [2005]

Upper gastrointestinal tolerability of once weekly alendronate 70 mg with concomitant non-steroidal anti-inflammatory drug use. [2005]

Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial. [2005]

Well-designed clinical trials possibly related to Binosto (Alendronate)

Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). [2014]

Ranking antireabsorptive agents to prevent vertebral fractures in postmenopausal osteoporosis by mixed treatment comparison meta-analysis. [2013]

[Efficacy of teriparatide in treatment of glucocorticoid-induced osteoporosis]. [Article in Japanese] [2012]

Bone turnover markers and bone mineral density response with risedronate therapy: relationship with fracture risk and patient adherence. [2011]

Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. [2011]

Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. [2010]

Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. [2010]

Does a history of non-vertebral fracture identify women without osteoporosis for treatment? [2008]

Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. [2007]

[Randomized controlled trials for the prevention and treatment of glucocorticoid-induced osteoporosis]. [Article in Japanese] [2006]

Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis. [2006]

Denosumab in postmenopausal women with low bone mineral density. [2006]

Once-monthly ibandronate. [2005]

Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a 12-month, randomized, placebo-controlled study. [2005]

Other research related to Binosto (Alendronate)

Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study. [2014]

A model of BMD changes after alendronate discontinuation to guide postalendronate BMD monitoring. [2014]

Endoscopic comparison of alendronate alone and the enteric-coated alendronate with calcitriol combination in postmenopausal Korean females. [2013]

Effect of early administration of alendronate after surgery for distal radial fragility fracture on radiological fracture healing time. [2013]

Comparison of alendronate and raloxifene for the management of primary hyperparathyroidism. [2013]

Alendronate treatment for hip osteoarthritis: prospective randomized 2-year trial. [2013]

BMD changes and predictors of increased bone loss in postmenopausal women after a 5-year course of alendronate. [2013]

A comparative study of the effects of daily minodronate and weekly alendronate on upper gastrointestinal symptoms, bone resorption, and back pain in postmenopausal osteoporosis patients. [2013]

Efficacy of a combined alendronate and calcitriol agent (Maxmarvil®) in Korean postmenopausal women with early breast cancer receiving aromatase inhibitor: a double-blind, randomized, placebo-controlled study. [2013]

Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis. [2013]

Efficacy of subgingivally delivered simvastatin in the treatment of patients with type 2 diabetes and chronic periodontitis: a randomized double-masked controlled clinical trial. [2013]

Bone loss after heart transplant: effect of alendronate, etidronate, calcitonin, and calcium plus vitamin D3. [2012]

[Clinical application of alendronate for osteoporosis/osteopenia secondary to hyperthyroidism]. [Article in Chinese] [2012]

Bone density around endosseous implants in patients taking alendronate: a pilot study. [2012]

Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis. [2012]

Alendronate in the prevention of collapse of the femoral head in nontraumatic osteonecrosis: a two-year multicenter, prospective, randomized, double-blind, placebo-controlled study. [2012]

Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study. [2012]

Comparative evaluation of isosorbide mononitrate and alendronate in management of postmenopausal osteoporosis. [2012]

Comparison of alendronate and pamidronate on bone loss in kidney transplant patients for the first 6 months of transplantation. [2011]

A comparison of the effects of alendronate and alfacalcidol on bone mineral density around the femoral implant and in the lumbar spine after total hip arthroplasty. [2011]

Other possibly related research studies

What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics. [2012]

Adherence to bisphosphonate therapy in postmenopausal osteoporotic women. [2011]

Bisphosphonates for osteoporosis in primary biliary cirrhosis. [2011]

Prevention of disuse osteoporosis in rats by Cordyceps sinensis extract. [2012]

Development, reliability, and validity of a new Preference and Satisfaction Questionnaire. [2011]

Ronacaleret, a calcium-sensing receptor antagonist, increases trabecular but not cortical bone in postmenopausal women. [2012]

Efficacy of different therapeutic regimens on hepatic osteodystrophy in chronic viral liver disease. [2011]

Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease--the DIVINE study. [2011]

The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women. [2011]

Delayed/non-union of upper limb fractures with bisphosphonates: systematic review and recommendations. [2014]

A Surgeon's guide to advances in the pharmacological management of acute Charcot neuroarthropathy. [2013]

Comparison of non-vertebral fracture between minodronate and risedronate therapy in elderly female patients with Alzheimer disease. [2013]

Pure and hybrid causal effects on variables associated with an incident event. [2013]

Interventions for preventing falls in people after stroke. [2013]

Influence of patient perceptions and preferences for osteoporosis medication on adherence behavior in the Denosumab Adherence Preference Satisfaction study. [2014]

Tooth extraction in osteoporotic patients taking oral bisphosphonates. [2013]

Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis. [2013]

Single and combined use of human parathyroid hormone (PTH) (1-34) on areal bone mineral density (aBMD) in postmenopausal women with osteoporosis: evidence based on 9 RCTs. [2014]

Anti-reabsorptive agents in women with osteoporosis: determining statistical equivalence according to evidence-based methods. [2014]

Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: a dose-response-based meta-analysis. [2014]

Bisphosphonates in the management of thalassemia-associated osteoporosis: a systematic review of randomised controlled trials. [2014]

Change in arterial stiffness associated with monthly bisphosphonate treatment in women with postmenopausal osteoporosis. [2014]

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017